Australija - engleski - APVMA (Australian Pesticides and Veterinary Medicines Authority)

bell laboratories, inc. - brodifacoum - bait - brodifacoum coumarin active 0.05 g/kg - vertebrate poison - agricultural area - general | commercial area - general | commercial/industrial premises | domestic and/or public area | premise - black rat | brown rat | mouse - mus spp.

Australija - engleski - APVMA (Australian Pesticides and Veterinary Medicines Authority)

bell laboratories, inc. - brodifacoum; denatonium benzoate - bait - brodifacoum coumarin active 0.05 g/kg; denatonium benzoate carbamate other 0.0 undefined - vertebrate poison - agricultural area - general | commercial area - general | commercial/industrial premises | domestic and/or public area | premise - black rat | brown rat | mouse - mus spp.

Australija - engleski - APVMA (Australian Pesticides and Veterinary Medicines Authority)

bell laboratories, inc. - bromadiolone - bait - bromadiolone coumarin active 0.05 g/kg - vertebrate poison - building | commercial/industrial premises | domestic and/or public area | farm and/or animal housing | food processing and/or pr - mouse - mus spp. | rat

Australija - engleski - APVMA (Australian Pesticides and Veterinary Medicines Authority)

bell laboratories, inc. - bromadiolone - bait - bromadiolone coumarin active 0.05 g/kg - vertebrate poison - building | commercial/industrial premises | domestic and/or public area | farm and/or animal housing | food processing and/or pr - mouse - mus spp. | rat

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - nonacog alfa 1000 [iu] (actually contains 1100 iu which includes 10% overage); nonacog alfa 1000 [iu] (actually contains 1100 iu which includes 10% overage) - powder for injection with diluent - 1000 iu - active: nonacog alfa 1000 [iu] (actually contains 1100 iu which includes 10% overage) excipient: glycine histidine polysorbate 80 sucrose water for injection active: nonacog alfa 1000 [iu] (actually contains 1100 iu which includes 10% overage) excipient: glycine histidine polysorbate 80 sucrose sodium chloride water for injection - for the control and prevention of haemorrhagic episodes in patients with haemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings.

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - nonacog alfa 250 [iu] (actual amount is 275 iu which includes 10% overage); nonacog alfa 250 [iu] (actual amount is 275 iu which includes 10% overage) - powder for injection with diluent - 250 iu - active: nonacog alfa 250 [iu] (actual amount is 275 iu which includes 10% overage) excipient: glycine histidine polysorbate 80 sucrose water for injection sodium chloride water for injection active: nonacog alfa 250 [iu] (actual amount is 275 iu which includes 10% overage) excipient: glycine histidine polysorbate 80 sucrose - for the control and prevention of haemorrhagic episodes in patients with haemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings.

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - nonacog alfa 500 [iu] (actually contains 550 iu which includes 10% overage); nonacog alfa 500 [iu] (actually contains 550 iu which includes 10% overage) - powder for injection with diluent - 500 iu - active: nonacog alfa 500 [iu] (actually contains 550 iu which includes 10% overage) excipient: glycine histidine polysorbate 80 sucrose water for injection active: nonacog alfa 500 [iu] (actually contains 550 iu which includes 10% overage) excipient: glycine histidine polysorbate 80 sucrose sodium chloride water for injection - for the control and prevention of haemorrhagic episodes in patients with haemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings.

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

nostrum laboratories, inc. - carbamazepine (unii: 33cm23913m) (carbamazepine - unii:33cm23913m) - carbamazepine 100 mg - carbamazepine extended-release capsules are indicated for use as an anticonvulsant drug. evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types:      - partial seizures with complex symptomatology (psychomotor, temporal lobe). patients with these seizures appear to show greater improvements than those with other types. - generalized tonic-clonic seizures (grand mal). - mixed seizure patterns which include the above, or other partial or generalized seizures. absence seizures (petit mal) do not appear to be controlled by carbamazepine (see precautions, general ). carbamazepine extended-release capsules are indicated in the treatment of the pain associated with true trigeminal neuralgia. beneficial results have also been reported in glossopharyngeal neuralgia. this drug is not a simple analgesic and should not be used for the relief of trivial aches or pains. carbamazepine should not be used in patients with a history of previous bone marrow depression, hypersensitivity to the drug, or known sensitivity to any of the tricyclic compounds, such as amitriptyline, desipramine, imipramine, protriptyline and nortriptyline. likewise, on theoretical grounds its use with monoamine oxidase inhibitors is not recommended. before administration of carbamazepine, mao inhibitors should be discontinued for a minimum of 14 days, or longer if the clinical situation permits. coadministration of carbamazepine and nefazodone may result in insufficient plasma concentrations of nefazodone and its active metabolite to achieve a therapeutic effect. coadministration of carbamazepine with nefazodone is contraindicated. coadministration of carbamazepine extended-release capsules are contraindicated with delavirdine due to the potential for loss of virologic response and possible resistance to delavirdine or to the class of non-nucleoside reverse transcriptase inhibitors. no evidence of abuse potential has been associated with carbamazepine, nor is there evidence of psychological or physical dependence in humans.

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

nostrum laboratories, inc. - carbamazepine (unii: 33cm23913m) (carbamazepine - unii:33cm23913m) - carbamazepine 300 mg - carbamazepine extended-release capsules are indicated for use as an anticonvulsant drug. evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: - partial seizures with complex symptomatology (psychomotor, temporal lobe). patients with these seizures appear to show greater improvements than those with other types. - generalized tonic-clonic seizures (grand mal). - mixed seizure patterns which include the above, or other partial or generalized seizures. absence seizures (petit mal) do not appear to be controlled by carbamazepine (see precautions, general). carbamazepine extended-release capsules are indicated in the treatment of the pain associated with true trigeminal neuralgia. beneficial results have also been reported in glossopharyngeal neuralgia. this drug is not a simple analgesic and should not be used for the relief of trivial aches or pains. carbamazepine should not be used in patients

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

novel laboratories, inc. - methylphenidate hydrochloride (unii: 4b3sc438hi) (methylphenidate - unii:207zz9qz49) - methylphenidate hydrochloride 5 mg - attention deficit disorders, narcolepsy attention deficit disorders  (previously known as minimal brain dysfunction in children). other terms being used to describe the behavioral syndrome below include: hyperkinetic child syndrome, minimal brain damage, minimal cerebral dysfunction, minor cerebral dysfunction. methylphenidate hydrochloride is indicated as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. the diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. nonlocalizing (soft) neurological signs, learning disability, and abnormal eeg may or may not be present, and a diagnosis of central nervous system dysfun